Equities

OncoTherapy Science Inc

OncoTherapy Science Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)30.00
  • Today's Change0.00 / 0.00%
  • Shares traded42.20m
  • 1 Year change-16.67%
  • Beta1.2411
Data delayed at least 20 minutes, as of May 29 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

  • Revenue in JPY (TTM)610.12m
  • Net income in JPY-1.29bn
  • Incorporated2001
  • Employees60.00
  • Location
    OncoTherapy Science Inc1-2, Higashida-cho, Kawasaki-kuKAWASAKI-SHI 210-0005JapanJPN
  • Phone+81 442016429
  • Fax+81 442016473
  • Websitehttps://www.oncotherapy.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
KAINOS Laboratories, Inc.5.06bn637.97m5.22bn144.007.510.77036.901.03152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
Noile-Immune Biotech Inc311.30m-975.80m5.54bn28.00--1.04--17.80-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
Solasia Pharma KK408.00m-1.18bn5.61bn24.00--2.90--13.75-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
DNA Chip Research Inc490.46m-248.29m6.16bn36.00--8.40--12.56-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
Cyfuse Biomedical KK64.79m-645.40m6.16bn21.00--2.00--95.13-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
Chiome Bioscience Inc642.70m-1.30bn6.54bn51.00--5.18--10.17-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
MEDRx Co Ltd22.57m-770.66m6.68bn22.00--3.18--295.94-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.73bn872.00--0.30895.760.219-49.89-49.898,520.205,115.780.62682.142.70---0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.33-2.57-2.10-153.10--24.62-12.94
Carna Biosciences, Inc.1.58bn-1.03bn6.88bn67.00--1.95--4.35-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.11bn109.00--0.9912--1.53-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
OncoTherapy Science, Inc.610.12m-1.29bn7.18bn60.00--18.46--11.77-6.09-6.092.871.620.5139.087.69---108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Veritas In Silico Inc-100.00bn-100.00bn7.54bn15.00--3.20----------363.52------------------------40.94--0.00--101.54--123.38------
K Pharma Inc500.00m-221.98m7.87bn15.00--2.74--15.74-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
CellSeed Inc193.68m-892.21m8.73bn35.00--4.19--45.06-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.74bn292.0079.950.724489.441.133.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
Tsubota Laboratory Inc673.53m-641.32m9.21bn10.00--6.73--13.67-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Data as of May 29 2024. Currency figures normalised to OncoTherapy Science Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

4.22%Per cent of shares held by top holders
HolderShares% Held
Long Corridor Asset Management Ltd.as of 22 May 20249.70m4.22%
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.